🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Rare cancer patients need leadership like this: links.mkt3779.com/servlet/MailVi… Kudos to Harvard Medical School george demetri

Thanks Isaac Kohane and Harvard Medical School ! Prof Marcia Haigis and I view this as a team effort, looking forward to building even more bridges between our Boston community and the global experts in many subtypes of rare cancers, starting with those with gene fusions

Metabolic disorders including obesity, #MASLD, #MASH & #type2diabetes are recognized as contributors to cancer. Toronto, Daan J. Kloosterman & Leila Akkari (The Netherlands Cancer Institute) explore the influence of macrophages + T cells in metabolic-disorder associated cancers.👇 go.nature.com/4eThIit

A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy go.nature.com/4eEVVvo

Online Now: Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion dlvr.it/TFFc4P

Online Now: The hallmarks of cancer immune evasion dlvr.it/TFFy1H

Congrats to Jonathan Fletcher + Sebastian Bauer, the organizing committee and the logistic team for launching the very first GISTT Summit in Essen today. It‘s been too long since we had GIST-specific meetings! Familiar venue to FORTRESSians and very familiar collaborative spirit

“As a doctor, it's just amazing to see these [cellular therapy] treatments in clinical practice. My hope is companies continue to invest in them to benefit our patients,” stated Dana-Farber’s Vinayak Venkataraman, MD during the #IVBM panel presentation. ➡️ bit.ly/3NCPm0j

Cancer Chemotherapy Cancer Cell

⁦Candace Haddox, MD⁩ presenting SARC044 for patients with #GIST. Trial now open ⁦Dana-Farber⁩ #ctos

Thank you @seppobauer for sharing GISTT Summit updates with takehome message "persistence is the ultimate roadblock to #GIST" and we should invest in understanding signalling pathways and needing novel clinical trials #CTOS2024

IDRX-42 a novel KIT TKI (targeting KIT ex 9, 11, 13 and 17 mut.) shows promising activity in phase I STRATEGIST 1 trial in pts with 2+ line of therapy 🔸ORR 29%, 53% in 2nd line 👏great presentation by Suzanne George Dana-Farber #CTOS2024 CTOS #CTOSTweeTOS

Dana-Farber Vinayak Venkataraman, MD george demetri

It is an absolute joy and honor to work which such extraordinary colleagues every day. Multidisciplinary team science is the way.

Grateful for the opportunity to present the work that my Lab is doing Brigham and Women’s Department of Surgery Dana-Farber’s Breast Oncology Center Harvard Medical School to target macrophages, which has led to a new clinical trial for breast cancer patients. Proud of my incredible team.

🟡 Here’s your weekly digest of my new Sarcoma Talk! I had the pleasure of speaking with Dr. Michael Wagner a leading expert in sarcoma from Dana-Farber. 💬 Wait for more episodes coming soon on OncoDaily TV! youtube.com/watch?v=dvR_b3… #sarcoma

My two NIH cancer research grants were terminated today. One involving breast cancer prevention is an “outstanding investigator award” and had received a perfect score by reviewers. How does ending lifesaving cancer research make Americans healthier? Harvard Medical School @aacr

Despite the unprecedented challenges we are facing in 2025, I am in awe of our Harvard Medical School team keeping their laser-focus on game-changing medical discoveries. I am immensely proud of their hard work – day and night – nailing what we do best: · Pioneering biomarkers

Did you know #sarcoma is common in dogs? Ruby had some great ideas for how to help her canine friends 🐶 #ASCO25

🗣️ We're hiring a Director of Preclinical Research! This is an exciting opportunity for an oncology R&D leader to make a tangible impact in the lives of patients in urgent need of new treatment options. More info: chordoma.org/team/careers/